Brief: Magenta Therapeutics - On March 31, Co Entered Into Sublease Termination, Release Agreement With Novartis Institutes For Biomedical Research

Dianthus Therapeutics

06/04/2023 13:38

April 6 (Reuters) - Magenta Therapeutics Inc  MGTA.O :
    * MAGENTA THERAPEUTICS - ON MARCH 31, CO ENTERED INTO
SUBLEASE
TERMINATION, RELEASE AGREEMENT WITH NOVARTIS INSTITUTES FOR
BIOMEDICAL RESEARCH
    * MAGENTA THERAPEUTICS INC - IN EXCHANGE FOR EARLY
TERMINATION OF
SUBLEASE AGREED TO MAKE ONE-TIME TERMINATION PAYMENT TO NOVARTIS
OF $14.8 MILLION
    * MAGENTA THERAPEUTICS - POST TERMINATION DATE, CO'S
PRINCIPAL
EXECUTIVE OFFICES WILL BE LOCATED AT 300 TECHNOLOGY SQUARE IN
CAMBRIDGE, MASSACHUSETTS

Further company coverage:  MGTA.O 

 ((Reuters.Briefs@thomsonreuters.com;))